PMID- 30619967
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2423-3439 (Print)
IS  - 2423-3420 (Electronic)
IS  - 2423-3420 (Linking)
VI  - 4
IP  - 3
DP  - 2018 Sep
TI  - Invasive candidiasis and candidemia in pediatric and neonatal patients: A review 
      of current guidelines.
PG  - 28-33
LID - 10.18502/cmm.4.3.173 [doi]
AB  - Several international and national guidelines have been proposed for the 
      treatment and prevention of invasive candidiasis/candidemia (IC/C) in both 
      neonatal and pediatric patients. This article is a review of the current 
      guidelines, recommendations, and expert panel consensus of a number of 
      associations and conferences on the prevention and management of IC and 
      candidemia in both pediatric and neonatal patients. The investigated resources 
      included the Infectious Diseases Society of America, the European Conference on 
      Infection in Leukaemia, the European Society of Clinical Microbiology and 
      Infectious Diseases, the German Speaking Mycological Society/Paul-Ehrlich Society 
      for Chemotherapy, as well as the Canadian, Middle Eastern, and Australian 
      guidelines. Echinocandins and liposomal amphotericin B (L-AmB) are the first-line 
      agents in the treatment of IC and candidemia both for immunocompetent and 
      immunocompromised pediatric patients. The recommendations suggested to keep 
      patients under sterile conditions for at least 14 days after blood cultures as 
      the prompt initiation of antifungal treatment. Guidelines addressing the neonates 
      recommended to use L-AmB, deoxycholate AmB (D-AmB), and fluconazole based on 
      three main principles of no previous exposure to azoles, the prompt initiation of 
      antifungal treatment, and control of predisposing underlying conditions. Despite 
      minor differences among the investigated guidelines, general treatment 
      recommendations suggest the prompt initiation of antifungal treatment and control 
      of all predisposing underlying conditions.
FAU - Vasileiou, Eleni
AU  - Vasileiou E
AD  - Hematology Oncology Unit, Pediatric Department of Aristotle University of 
      Thessaloniki, AHEPA General Hospital, Thessaloniki, Greece.
FAU - Apsemidou, Athanasia
AU  - Apsemidou A
AD  - Department of Internal Medicine, Papanikolaou General Hospital, Thessaloniki, 
      Greece.
FAU - Vyzantiadis, Timoleon-Achilleas
AU  - Vyzantiadis TA
AD  - Department of Microbiology, Medical School, Aristotle University of Thessaloniki, 
      Thessaloniki, Greece.
FAU - Tragiannidis, Athanasios
AU  - Tragiannidis A
AD  - Hematology Oncology Unit, Department of Pediatric, Aristotle University of 
      Thessaloniki, AHEPA General Hospital, Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Iran
TA  - Curr Med Mycol
JT  - Current medical mycology
JID - 101647935
PMC - PMC6315202
OTO - NOTNLM
OT  - Candidemia
OT  - Children
OT  - Guidelines
OT  - Invasive candidiasis
OT  - Neonates
OT  - Prevention
OT  - Treatment
COIS- The authors declare no conflicts of interest and are responsible for the content 
      and writing of the paper.
EDAT- 2019/01/09 06:00
MHDA- 2019/01/09 06:01
PMCR- 2018/09/01
CRDT- 2019/01/09 06:00
PHST- 2019/01/09 06:00 [entrez]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2019/01/09 06:01 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - 10.18502/cmm.4.3.173 [doi]
PST - ppublish
SO  - Curr Med Mycol. 2018 Sep;4(3):28-33. doi: 10.18502/cmm.4.3.173.